S. Skinner

发表

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Henry C Kitchener, Bart Spiessens, Frank Struyf, 2007, The Lancet.

Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study

C. Wheeler, S. Garland, X. Castellsagué, 2013, PloS one.

Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.

H. Kitchener, M. Lehtinen, D. Harper, 2012, Gynecologic oncology.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

D. Lowy, C. Wheeler, S. Wacholder, 2015, The Lancet. Oncology.

Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis

J. Lew, M. Kelaher, S. Skinner, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation

M. Lehtinen, D. Harper, S. Garland, 2013, The Journal of infectious diseases.

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, The Lancet. Oncology.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, The Lancet. Oncology.

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

B Romanowski, H. Kitchener, M. Lehtinen, 2009, The Lancet.

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

C. Wheeler, M. Lehtinen, D. Harper, 2017, Journal of the National Cancer Institute.

Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

D. Harper, D. Apter, J. Paavonen, 2016, Expert review of vaccines.

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

C. Wheeler, H. Kitchener, M. Lehtinen, 2015, Clinical and Vaccine Immunology.

Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA

Frank Struyf, Brigitte Colau, Cosette M Wheeler, 2014, Clinical and Vaccine Immunology.

Clinical update

S. Garland, M. Pitts, K. Hertlein, 2022 .

Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, International journal of cancer.

Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials

S. Wacholder, M. Sherman, M. Schiffman, 2018, The Journal of infectious diseases.

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial

M. Lehtinen, S. Garland, X. Castellsagué, 2016, International journal of cancer.

Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA

C. Wheeler, H. Kitchener, M. Lehtinen, 2014, The Journal of infectious diseases.

Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.

J. Kaldor, S. Garland, A. McNulty, 2021, Vaccine.